O63 EFFICACY AND SAFETY OF THE ALL-ORAL REGIMEN, MK-5172/MK-8742 +/− RBV FOR 12 WEEKS IN GT1 HCV/HIV CO-INFECTED PATIENTS: THE C-WORTHY STUDY
暂无分享,去创建一个
J. Mallolas | S. Pol | O. Shibolet | M. Sulkowski | M. Bourlière | B. Haber | E. Dejesus | R. Nahass | J. Gerstoft | M. Robertson | J. Wahl | M. Shaughnessy | P. Hwang